Ultragenyx Pharmaceutical Inc. (LON:0LIF)

London · Delayed Price · Currency is GBP · Price in USD

23.87

-0.59 (-2.40%)

At close: Feb 11, 2026

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
North America Revenue	-	340.46M
North America Revenue Growth	-	10.85%
Latin America Revenue	-	130.71M
Latin America Revenue Growth	-	69.01%
Europe Revenue	-	80.12M
Europe Revenue Growth	-	68.56%
Asia-Pacific Revenue	-	8.93M
Asia-Pacific Revenue Growth	-	301.53%
Revenue (Total)	673.00M	560.23M
Revenue (Total) Growth	20.13%	29.01%

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Crysvita Revenue	177.00M	134.71M
Crysvita Revenue Growth	31.39%	77.96%
Dojolvi Revenue	96.00M	88.19M
Dojolvi Revenue Growth	8.85%	24.86%
Evkeeza Revenue	59.00M	32.16M
Evkeeza Revenue Growth	83.45%	783.09%
Mepsevii Revenue	37.00M	30.35M
Mepsevii Revenue Growth	21.91%	-0.30%
Total Product Revenue	369.00M	285.42M
Total Product Revenue Growth	29.29%	58.20%
Crysvita Royalty Revenue	304.00M	274.82M
Crysvita Royalty Revenue Growth	10.62%	50.46%
Revenue (Other)	-	-
Revenue (Total)	673.00M	560.23M
Revenue (Total) Growth	20.13%	29.01%

Updated Dec 31, 2025. Data Source: Fiscal.ai.